Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lakewood-Amedex BiotherapeuticsLABT 8 Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100. Among 837 Biotechnology companies, Lakewood-Amedex Biotherapeutics ranks worse than 119474.19% on this metric.
The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's Days Sales Outstanding or its related term are showing as below:
LABT's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.03 * Ranked among companies with meaningful Days Sales Outstanding only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics Days Sales Outstanding Chart
LABT vs CDIO, JAGX, TCRT: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakewood-Amedex Biotherapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Days Sales Outstanding falls into.
Lakewood-Amedex Biotherapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics (LABT) has a Days Sales Outstanding of 0.00 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 837 companies in the Biotechnology industry.
Is Lakewood-Amedex Biotherapeutics' Days Sales Outstanding too high?
Lakewood-Amedex Biotherapeutics' current Days Sales Outstanding is 0.00. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 837 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Days Sales Outstanding compare to CDIO and JAGX?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 837 companies for Days Sales Outstanding. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 69.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.03, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakewood-Amedex Biotherapeutics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score
Get the complete analysis for LABT
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABT has been successfully added to your 
